Some obstetric and gynecological conditions require innovative treatment methods. The Methodist Hospital is at the forefront of women’s health care with breakthrough procedures and treatments, thanks to extensive research and a highly educated staff. We are proud to be able to offer you leading-edge care for conditions such as cancer, infertility and high-risk pregnancies, all handled with the caring and personal touch you expect from Methodist.
- Surgical and Medical Clinical Trials
- Chemosensitivity Assay
- Minimally Invasive Surgery
- Targeted Therapy with Bevacizumab (Avastin)
- Gynecologic Oncology Group (GOG) Research
As part of our ongoing commitment to groundbreaking research and advances in cancer therapy, The Methodist Hospital offers our patients the opportunity to participate in surgical and medical clinical trials. Please click here for information on our current studies. If you are interested in being a candidate for one of these trials, please talk to your physician and contact Dr. Carol Hodgson at 713-441-6616 to find out if you meet the criteria for participation.
We invite you to learn more about our clinical trials, including the types of trials we conduct, the benefits of participation and our commitment to patient safety.
A chemosensitivity assay is a test that is particularly useful in the treatment of recurrent cancers. This analysis involves removing cells from a tumor and determining their response to different combinations of chemotherapy medicines. As every patient is different, there is no single chemotherapy treatment that will work well for everyone; therefore, the chemosensitivity assay enables your physician to determine what your most effective course of treatment will be before administering any chemotherapy to you.
Methodist Obstetrics and Gynecology Group is able to treat a wide range of women's health issues using minimally invasive surgery – surgical procedures that use small (or no) incisions and result not only in greater precision for our surgeons, but a faster recovery time for you. Some of our frequently used methods include:
- Laparoscopic surgery: in this procedure, a surgery is performed using a special tool known as a laparoscope – a thin, lighted tube with a tiny camera attached. Using this laparoscope, a surgeon is able to view and remove areas of disease using only small incisions.
- Hysteroscopic surgery: similar to laparoscopic surgery, this surgery involves the use of a narrow tube-like instrument outfitted with a light and a camera; however, a hysteroscope usually requires no incisions, as the tool can be inserted directly into the uterus through the vagina and cervix. Hysteroscopic surgery is useful for retrieving samples for diagnosis and for performing endometrial ablation – the removal of the lining of the uterus – as a possible alternative to a hysterectomy (removal of the entire uterus). The procedure can also be used to treat uterine fibroids.
- da Vinci System: this robotic “assistant” gives your surgeon greater control over his or her movements and provides a highly magnified 3-D image of the area to be operated upon. The Methodist Hospital has four of these systems available for surgery – more than any other hospital in the area. For more on this system, click here.
- Laser surgery: In conditions such as vulvar or vaginal dysplasia or very early stage cancer, laser ablation may be an option. Laser ablation involves destruction of the abnormal cells using a beam of intense light, and requires no incision.
Bevacizumab, commonly known by the name Avastin, is a revolutionary addition to traditional chemotherapy. This treatment is known as an anti-angiogenic agent, meaning it prevents angiogenesis, or the growth of new blood vessels in a tumor. Although it is not a chemotherapy drug – it is a biotherapy, or a treatment that works with one’s immune system – it is meant to be used in conjunction with chemotherapy treatment.
Bevacizumab works by inhibiting a special protein called a growth factor. This protein causes the body to create new blood vessels and promotes the growth of cancer cells. Tests have proven this therapy to be effective for certain types of metastatic breast cancer. Bevacizumab is the first therapy of this kind to be approved by the FDA.
The Gynecologic Oncology Group (GOG) is a nonprofit, multidisciplinary cancer research group funded by the National Cancer Institute. Methodist Obstetrics and Gynecology Group is a GOG member and clinical trial site.
Founded in 1970 as a collaborative network among the world’s most prestigious medical institutions, the GOG is the only group of its kind to specifically focus upon gynecological cancers. Among the GOG’s member institutions – including The Methodist Hospital - more than 300 clinical trials have been conducted, resulting in breakthrough treatment advances for endometrial, cervical and ovarian cancer. Thanks to this membership, Methodist enjoys the benefit of a strong and far-reaching alliance and a cooperative exchange of information.